Med2Date β€” Clinical Guidelines
Home Immunology Vaccination

Vaccination

Last updated 31 May 2026 Β· Immunology clinical guideline

πŸ“‹ Key Information Summary

πŸ“‹
  • Vaccination is the single most effective public health intervention for preventing infectious diseases, saving an estimated 3.5–5 million lives globally each year (WHO, 2024).
  • Seven major vaccine platform types are used in Australia: live attenuated, inactivated whole-organism, subunit/recombinant, toxoid, conjugate polysaccharide, mRNA, and viral vector β€” each with distinct immunological profiles and contraindication sets.
  • Protective immunity requires both humoral (antibody) and cellular (T-cell) responses; correlates of protection vary by disease (e.g., anti-HBs β‰₯10 IU/L for hepatitis B).
  • Adjuvants enhance vaccine immunogenicity by activating innate immune pathways; common adjuvants in Australia include aluminium salts, AS01B (Shingrix), AS04 (Cervarix), and MF59 (Fluad Quad).
  • Herd immunity thresholds differ by pathogen: measles requires ~95% coverage, pertussis ~92%, polio ~80–86% β€” current MMR second-dose coverage in Australian 5-year-olds is 94.7%.
  • The National Immunisation Program (NIP) Schedule covers vaccines from birth through to β‰₯65 years; all NIP vaccines are provided free to eligible Australians.
  • Live vaccines are contraindicated in pregnancy and severely immunocompromised patients; inactivated and mRNA vaccines are generally safe in these groups.
  • Aboriginal and Torres Strait Islander peoples experience higher burden of vaccine-preventable diseases and have targeted NIP schedules (e.g., additional influenza and pneumococcal vaccines).
  • Serological testing can confirm immune response post-vaccination in high-risk settings (healthcare workers, immunocompromised patients) β€” MBS item 69411 for anti-HBs quantitation.
  • Cold-chain integrity (2–8Β°C) must be maintained for all non-mRNA vaccines; mRNA vaccines (Comirnaty) require βˆ’60 to βˆ’80Β°C for long-term storage, 2–8Β°C for up to 30 days after thawing.
  • Anaphylaxis to vaccines is rare (~1.3 per million doses) but requires 15-minute post-vaccination observation and availability of adrenaline autoinjectors.
  • Catch-up vaccination should be initiated promptly for under-vaccinated individuals of all ages; the Australian Immunisation Register (AIR) provides real-time coverage data.
  • Co-administration of multiple vaccines at different anatomical sites is safe and recommended per the ATAGI guidelines; minimum intervals apply only between doses of the same antigen.

Introduction & Australian Epidemiology

Vaccination harnesses immunological memory to provide protective immunity against infectious diseases through administration of antigens or attenuated pathogens. Since Edward Jenner's pioneering use of cowpox material in 1796, vaccination has eradicated smallpox, brought polio to the brink of elimination, and dramatically reduced the global burden of diphtheria, tetanus, measles, and pertussis.

Australia maintains one of the world's most comprehensive publicly funded vaccination programmes. The National Immunisation Program (NIP) Schedule, administered through the Australian Government Department of Health and Aged Care, provides free vaccines at birth, 2 months, 4 months, 6 months, 12 months, 18 months, 4 years, and through school-based programmes at 12–13 years, as well as catch-up programmes and adult/elderly schedules.

Current Australian coverage data (2023–2024):

  • 12-month-olds: 94.6% fully immunised (NIP schedule antigens)
  • 24-month-olds: 91.2% fully immunised
  • 60-month-olds (5 years): 94.7% fully immunised
  • Influenza vaccination (β‰₯65 years): ~73% coverage
  • COVID-19 primary course: >95% of adults aged β‰₯16 years

Despite these high national averages, significant disparities persist. Aboriginal and Torres Strait Islander children have lower 5-year vaccination completion rates in some jurisdictions, and pockets of under-vaccination exist in regional and outer-metropolitan areas associated with vaccine hesitancy, access barriers, and socioeconomic disadvantage.

⚠️
Vaccine hesitancy is a growing threat: The WHO identified vaccine hesitancy as one of the top 10 threats to global health in 2019. In Australia, the 'No Jab, No Pay' and 'No Jab, No Play' policies have improved coverage but ongoing community engagement and GP-led counselling remain essential.

The Australian Technical Advisory Group on Immunisation (ATAGI) provides ongoing recommendations to the Australian Government, and the Australian Immunisation Handbook (published by the Department of Health and Aged Care) serves as the authoritative clinical reference for vaccine providers.

Vaccination clinical infographic β€” pathophysiology, clinical clues, diagnosis, imaging, and management
Tap or click image to enlarge β€” Vaccination: pathophysiology, clinical clues, diagnosis, imaging, and management.
Vaccination infographic, full size

Types of Vaccines

Vaccines are classified by their antigen composition and manufacturing process. Each platform has distinct advantages, limitations, and contraindication profiles. Understanding these differences is essential for appropriate selection, particularly in special populations.

Vaccine Type Mechanism Australian Examples (NIP) Key Features
Live attenuated Weakened replicating pathogen stimulates broad immune response MMR (Priorix), Varicella (Varilrix), Rotavirus (Rotarix), BCG, Oral polio (not currently NIP), Yellow fever, Zostavax Strong, durable immunity; usually fewer doses needed. Contraindicated in pregnancy and severe immunodeficiency.
Inactivated whole-organism Killed pathogen; presents multiple antigens without replication Influenza (inactivated), Hepatitis A (Havrix), IPV (Infanrix Hexa component), Rabies (Rabipur) Safe in immunocompromised patients; generally requires adjuvant; multiple doses often needed for primary series.
Subunit / Recombinant protein Purified or recombinant antigen(s); minimal reactogenicity Hepatitis B (Engerix-B, HB-Vax II), HPV (Gardasil 9), Pertussis acellular (Infanrix Hexa component), Shingrix (recombinant varicella zoster glycoprotein E) Excellent safety profile; adjuvant-dependent; specific antigen only.
Toxoid Inactivated toxin (formaldehyde-treated); induces anti-toxin antibodies Diphtheria toxoid, Tetanus toxoid (both in Infanrix Hexa, Boostrix) Protects against disease pathology (toxin), not necessarily colonisation. Boosters every 10 years in adults.
Conjugate polysaccharide Capsular polysaccharide linked to protein carrier β†’ T-dependent immune response MenACWY (Nimenrix), Pneumococcal 13v (Prevenar 13), Hib (Act-HIB in Infanrix Hexa) Effective in children <2 years (unlike plain polysaccharide); immunological memory generated.
mRNA Lipid nanoparticle-encapsulated mRNA encoding target antigen; host cells produce protein Comirnaty (Pfizer COVID-19), Spikevax (Moderna COVID-19) Rapid development; strong humoral and cellular immunity; cold-chain requirements (βˆ’60 to βˆ’80Β°C storage).
Viral vector Non-replicating viral vector delivers genetic material encoding target antigen Vaxzevria (AstraZeneca COVID-19 β€” no longer NIP) Single-dose potential; rare risk of thrombosis with thrombocytopenia syndrome (TTS).

Live Attenuated Vaccines β€” Detailed Considerations

Live vaccines replicate within the host, generating robust humoral and cellular immunity. However, they carry a risk of vaccine-strain disease in immunocompromised individuals:

  • Contraindicated in: Primary immunodeficiency, HIV with CD4 <200 cells/Β΅L, active chemotherapy, high-dose corticosteroids (β‰₯2 mg/kg/day prednisolone or β‰₯20 mg/day for β‰₯14 days), solid organ transplant on immunosuppression, pregnancy.
  • Safe in: HIV with CD4 β‰₯200 cells/Β΅L (with specialist guidance), patients on low-dose methotrexate (≀0.4 mg/kg/week), patients on biologics with appropriate washout periods.
  • Timing: Wait β‰₯4 weeks after live vaccine before commencing immunosuppressive therapy. After stopping immunosuppression, wait β‰₯1–3 months (depending on agent) before live vaccination.

mRNA Vaccines β€” Australian Context

mRNA vaccines have transformed COVID-19 response and are being investigated for influenza, RSV, and other pathogens. Key Australian considerations:

  • Comirnaty (Pfizer) and Spikevax (Moderna) are available on the NIP for COVID-19.
  • Storage: βˆ’60 to βˆ’80Β°C (Pfizer) for long-term; once thawed, 2–8Β°C for up to 30 days. Moderna can be stored at βˆ’15 to βˆ’25Β°C.
  • Myocarditis/pericarditis risk: estimated 1–4 per 100,000 doses (higher in males aged 12–30, dose 2 > dose 1). ATAGI recommends Comirnaty over Spikevax for <30 years due to lower myocarditis signal.
  • Safe in pregnancy and immunocompromised patients (inactivated-type safety profile).

Mechanisms of Protection

Vaccination protects by priming the adaptive immune system to respond rapidly and effectively upon subsequent pathogen exposure. This involves coordinated humoral and cellular immune responses that generate immunological memory β€” the cardinal goal of all vaccination.

Humoral Immunity (B-Cell / Antibody-Mediated)

  • Primary response: Antigen presentation to B-cells in germinal centres of lymph nodes β†’ clonal expansion β†’ IgM production (days 5–10), followed by class switching to IgG (day 10–14+).
  • Affinity maturation: Somatic hypermutation in germinal centres produces higher-affinity antibodies with each successive exposure.
  • Memory B-cells: Long-lived cells (decades) that rapidly differentiate into antibody-secreting plasma cells upon re-exposure.
  • Long-lived plasma cells: Reside in bone marrow; secrete antibodies continuously without re-exposure to antigen β€” basis for durable protection.
  • Functional antibody mechanisms: Neutralisation (blocking pathogen entry), opsonisation (enhanced phagocytosis), complement activation, antibody-dependent cellular cytotoxicity (ADCC).

Cellular Immunity (T-Cell-Mediated)

  • CD4+ helper T-cells: Th1 (intracellular pathogens), Th2 (extracellular pathogens/helminths), Tfh (germinal centre support for B-cells), Th17 (mucosal defence). Essential for coordinating both humoral and cellular responses.
  • CD8+ cytotoxic T-lymphocytes (CTLs): Kill virus-infected cells via perforin/granzyme pathway; critical for clearance of intracellular pathogens (e.g., varicella, influenza).
  • Central memory T-cells (Tcm): Reside in lymph nodes; rapidly expand upon re-encounter with antigen.
  • Tissue-resident memory T-cells (Trm): Positioned at mucosal surfaces (respiratory tract, gut); provide frontline defence at the site of pathogen entry.
πŸ’‘
Correlates of protection are measurable immune markers that predict clinical protection:
  • Hepatitis B: Anti-HBs β‰₯10 IU/L (protective level); some experts recommend β‰₯100 IU/L for healthcare workers.
  • Measles: Neutralising antibody titre β‰₯120 mIU/mL (varies by assay).
  • Tetanus: Anti-tetanus toxoid IgG β‰₯0.1 IU/mL (basic protection); β‰₯1.0 IU/mL (full protection).
  • Influenza: Haemagglutination inhibition (HAI) titre β‰₯1:40 (50% protective threshold).

Herd Immunity

When a sufficient proportion of a population is immune, the chain of transmission is interrupted, indirectly protecting unvaccinated individuals. The herd immunity threshold (HIT) is calculated as HIT = 1 βˆ’ 1/Rβ‚€, where Rβ‚€ is the basic reproduction number.

Disease Rβ‚€ Herd Immunity Threshold Target Vaccine Coverage
Measles12–1892–95%β‰₯95% (2 doses MMR)
Pertussis12–1792–94%β‰₯92% (primary series + boosters)
Polio5–780–86%β‰₯85% (IPV primary series)
Diphtheria6–783–86%β‰₯90% (primary series + boosters)
Influenza2–350–67%β‰₯75% (annual vaccination)
COVID-19 (Omicron)8–1587–93%High coverage reduces severity; sterilising immunity not achievable long-term

Adjuvants

Adjuvants are substances added to vaccines to enhance, accelerate, and prolong the adaptive immune response. They are essential for subunit and recombinant vaccines, which lack the intrinsic immunostimulatory signals of whole-organism preparations.

Mechanisms of Action

  • Depot formation: Aluminium salts create a local depot, slowly releasing antigen and prolonging immune exposure (days to weeks).
  • Activation of innate immunity: Pattern recognition receptors (TLRs, NLRs, RIG-I) are activated by adjuvant components, triggering inflammatory cytokine production and dendritic cell maturation.
  • Enhanced antigen presentation: Activated dendritic cells migrate to draining lymph nodes and more efficiently present antigen to T-cells.
  • Biasing of T-cell responses: Different adjuvants can skew toward Th1 (cell-mediated), Th2 (humoral), or balanced responses.

Adjuvants Used in Australian Vaccines

Adjuvant Composition Australian Vaccine(s) Key Properties
Aluminium hydroxide / phosphate Aluminium salts Hepatitis B (Engerix-B), HPV (Gardasil 9), DTPa (Infanrix Hexa), Pneumococcal 13v (Prevenar 13) Well-established safety profile (>90 years of use). Promotes Th2-biased responses. Injection-site reactions (pain, swelling) common.
AS01B MPL (monophosphoryl lipid A, TLR4 agonist) + QS-21 (saponin) in liposomes Shingrix (herpes zoster) Very potent; induces strong CD4+ T-cell and antibody responses. >90% efficacy against shingles even in elderly β‰₯80 years. Higher reactogenicity (myalgia, fever).
AS04 MPL adsorbed onto aluminium phosphate Cervarix (HPV β€” older formulation, now superseded by Gardasil 9 on NIP) TLR4 activation + depot effect. Strong antibody persistence (>11 years). Th1 + Th2 balanced response.
MF59 Squalene oil-in-water emulsion Fluad Quad (adjuvanted influenza for β‰₯65 years on NIP) Enhances antibody response in elderly; improves cross-protection against drifted strains. Not associated with autoimmune disease.
CpG 1018 Synthetic oligodeoxynucleotide (TLR9 agonist) Heplisav-B (hepatitis B β€” 2-dose schedule, available privately) Th1-biased response; higher seroprotection rates vs alum-adjuvanted hepatitis B vaccines. Allows 2-dose (0, 1 month) vs 3-dose schedule.
ℹ️
Adjuvant-related safety considerations: Aluminium-containing adjuvants have been extensively studied and are not associated with autoimmune disease, Alzheimer's disease, or autism. Injection-site nodules may persist for weeks (sterile abscess in ~0.01–0.1% of recipients). AS01B-adjuvanted vaccines (Shingrix) cause higher rates of systemic reactions (fever, malaise) that typically resolve within 48 hours.

Vaccine-Preventable Diseases

The following section covers the major vaccine-preventable diseases relevant to Australian clinical practice, with emphasis on epidemiology, vaccine type, NIP schedule, and clinical management.

Measles

Despite elimination status in Australia (achieved 2014), imported cases continue to cause outbreaks in under-vaccinated communities. Australia recorded 262 cases in 2023, predominantly linked to overseas travel.

  • Vaccine: MMR (Priorix) β€” live attenuated; NIP at 12 months + 18 months (or MMRV at 18 months). Second dose at 4 years (catch-up).
  • Efficacy: ~95% after one dose, ~99% after two doses.
  • Herd immunity threshold: β‰₯95% β€” requires high two-dose coverage.
  • Serological confirmation: Measles IgG positive (MBS item 69450). Non-immune healthcare workers require two documented MMR doses.

Influenza

Annual influenza vaccination is recommended for all Australians β‰₯6 months. NIP-funded for: β‰₯65 years, Aboriginal and Torres Strait Islander peoples β‰₯6 months, pregnant women, and individuals with specified medical risk factors.

πŸ’‰
Fluad Quad
Seqirus Β· MF59-adjuvanted quadrivalent influenza
Indication Adults β‰₯65 years (NIP-funded)
Dose 0.5 mL IM, single annual dose (March–May optimal)
Advantage Higher immunogenicity in elderly vs standard quadrivalent; improved efficacy against drifted strains
PBS status βœ” NIP-funded for β‰₯65 years
πŸ’‰
FluQuadri / Influvac Tetra
Seqirus / Abbott Β· Standard quadrivalent influenza
Indication All individuals β‰₯6 months (NIP for eligible groups; private script for others)
Dose 0.5 mL IM (β‰₯3 years) or 0.25 mL IM (6 months–3 years), annual
PBS status βœ” NIP for eligible groups Private script for others

Pneumococcal Disease

Streptococcus pneumoniae causes invasive pneumococcal disease (IPD), including bacteraemia, meningitis, and pneumonia. Australia has a significant burden in Aboriginal and Torres Strait Islander communities.

πŸ’‰
Prevenar 13 (13vPCV)
Pfizer Β· 13-valent pneumococcal conjugate vaccine
NIP schedule 2 months, 4 months, 12 months (3 doses primary series)
Dose 0.5 mL IM
PBS status βœ” NIP-funded (infants)
πŸ’‰
Pneumovax 23 (23vPPV)
Merck Β· 23-valent pneumococcal polysaccharide vaccine
Indication Adults β‰₯65 years; ATSI adults β‰₯50 years; immunocompromised β‰₯2 years
Dose 0.5 mL IM/SC; booster every 5 years for high-risk (immunocompromised, asplenia)
PBS status βœ” NIP-funded for eligible groups

COVID-19

SARS-CoV-2 vaccination remains a cornerstone of pandemic management in Australia. ATAGI recommends an annual COVID-19 vaccine for all adults β‰₯75 years, with consideration for 65–74 years and younger adults with risk factors.

πŸ’‰
Comirnaty (BNT162b2)
Pfizer Β· mRNA COVID-19 vaccine
Current recommendations Annual booster for β‰₯75 years; consider 65–74 years and risk factors; 2024 formulation (JN.1 lineage)
Dose 0.3 mL IM (standard); 0.3 mL IM (paediatric 5–11 years, orange cap vials)
Storage βˆ’60 to βˆ’80Β°C (long-term); 2–8Β°C up to 30 days after thaw; do not refreeze
PBS status βœ” NIP-funded
⚠️
Myocarditis/pericarditis risk: mRNA COVID-19 vaccines carry a small risk of myocarditis/pericarditis, particularly in males aged 12–30 years after the second dose. ATAGI recommends Comirnaty over Spikevax for individuals <30 years. Patients presenting with chest pain, dyspnoea, or palpitations within 7 days of mRNA vaccination should be evaluated urgently (troponin, ECG, echocardiogram).

Pertussis (Whooping Cough)

Pertussis remains a significant cause of infant morbidity and mortality in Australia, with cyclical epidemics every 3–4 years. Maternal vaccination during pregnancy (20–32 weeks) is critical for neonatal protection.

πŸ’‰
Boostrix
GSK Β· dTpa (diphtheria-tetanus-acellular pertussis)
Indication Booster in adolescents (12–13 years, NIP), adults, pregnant women (20–32 weeks)
Dose 0.5 mL IM; every pregnancy, every 10 years for adults
PBS status βœ” NIP-funded

Hepatitis B

Australia has maintained a universal infant hepatitis B vaccination programme since 2000. Adult vaccination targets high-risk groups, including healthcare workers, people who inject drugs, prisoners, and men who have sex with men.

πŸ’‰
Engerix-B
GSK Β· Recombinant hepatitis B surface antigen (HBsAg)
Adult dose 20 Β΅g (1.0 mL) IM at 0, 1, 6 months
Paediatric dose 10 Β΅g (0.5 mL) IM at birth, 2, 4, 6 months (NIP); accelerated schedule 0, 1, 2, 12 months for high-risk
Post-vaccination serology Anti-HBs β‰₯10 IU/L at 1–4 months post-dose 3 (MBS item 69411). Non-responders: repeat 3-dose series.
PBS status βœ” NIP-funded (infants/adolescents); PBS for adults at risk

Human Papillomavirus (HPV)

Australia is on track to become the first country to eliminate cervical cancer, largely due to the school-based HPV vaccination programme (since 2007) combined with the National Cervical Screening Programme.

πŸ’‰
Gardasil 9
Merck Β· 9-valent recombinant HPV vaccine
NIP schedule Single dose at 12–13 years (school-based programme); catch-up for those who missed.
Dose 0.5 mL IM. Immunocompromised individuals: 3-dose schedule (0, 2, 6 months).
Efficacy >90% protection against HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58. Australia's cervical cancer incidence dropped 50% in vaccinated cohorts.
PBS status βœ” NIP-funded

Herpes Zoster (Shingles)

Herpes zoster affects approximately 1 in 3 people during their lifetime. The AS01B-adjuvanted recombinant vaccine (Shingrix) has replaced the live attenuated vaccine (Zostavax) on the NIP from November 2023.

πŸ’‰
Shingrix
GSK Β· Recombinant varicella zoster glycoprotein E + AS01B adjuvant
Indication Adults β‰₯65 years (NIP); immunocompromised β‰₯18 years; ATSI adults β‰₯50 years
Dose 0.5 mL IM; 2 doses, 2–6 months apart
Efficacy >90% in all age groups including β‰₯80 years. Efficacy maintained at 7+ years.
Key note Non-live vaccine β€” safe in immunocompromised patients. Higher reactogenicity than Zostavax (expect injection-site pain, myalgia, fever in ~10–15%).
PBS status βœ” NIP-funded

Other Notifiable Vaccine-Preventable Diseases in Australia

Disease Vaccine (NIP) Schedule Notes
Diphtheria DTPa (Infanrix Hexa), dTpa (Boostrix) 2, 4, 6 months; 18 months; 4 years; 12–13 years; adult boosters q10y Toxoid vaccine; booster essential for ongoing protection.
Tetanus DTPa, dTpa As per diphtheria schedule; post-exposure: unvaccinated = TIG + dT Wound management: tetanus-prone wound in unvaccinated/partially vaccinated β†’ TIG 250 IU IM + dT vaccine.
Polio IPV (in Infanrix Hexa) 2, 4, 6 months; booster at 4 years Australia uses IPV only (no oral live vaccine).
Haemophilus influenzae type b (Hib) Hib conjugate (in Infanrix Hexa, Act-HIB) 2, 4, 6 months; booster at 12 months Dramatic reduction in invasive Hib disease since programme introduced.
Meningococcal ACWY Nimenrix (MenACWY) 12 months (NIP); school-based at 12–13 years Also covers MenB (Bexsero) for ATSI infants and high-risk groups (not routine NIP).
Rotavirus Rotarix (live oral) 2 months, 4 months (2-dose schedule) Must be completed by 24 weeks 6 days (dose 1) and 32 weeks 6 days (dose 2) due to intussusception risk window.
Varicella (Chickenpox) MMRV (Priorix-Tetra) or Varilrix 18 months (MMRV); second dose catch-up at 4 years Live vaccine; avoid in pregnancy. Two doses required for seroconversion in ~99%.
Hepatitis A Havrix Junior / Havrix 1440 ATSI children in NT, Qld, SA, WA: 12, 18 months Inactivated; not routinely funded for non-ATSI children.

Investigations

Serological testing plays an important role in confirming vaccine-induced immunity, particularly in high-risk groups. The following investigations are available in Australia through pathology services.

Available
Anti-HBs quantitation (Hepatitis B immunity)
MBS item 69411. Confirm seroprotection (β‰₯10 IU/L) 1–4 months post-dose 3 in healthcare workers, dialysis patients, immunocompromised. Non-responders: repeat 3-dose series; if still non-responsive, consider higher-dose vaccine or different brand.
Available
Measles IgG
MBS item 69450. Confirm immunity in healthcare workers, pregnant women (check rubella and varicella simultaneously). Positive = immune. Negative = give MMR (if not pregnant).
Available
Rubella IgG
MBS item 69480. Mandatory pre-conception and antenatal screening. Non-immune women: MMR postpartum (not during pregnancy).
Available
Varicella IgG
MBS item 69480. Confirm immunity in healthcare workers, immunocompromised contacts, pre-pregnancy. Non-immune: Varilrix (live) if not pregnant/immunocompromised.
Available
Anti-tetanus toxoid IgG
Check in unclear vaccination history or wound management. Protective: β‰₯0.1 IU/mL; fully protected: β‰₯1.0 IU/mL. If <0.1 IU/mL and tetanus-prone wound: TIG + dT.
Available
Influenza HAI titre
Research/specialist use. Correlate of protection: HAI β‰₯1:40 (50% protective). Not routinely performed clinically.
Specialist
Lymphocyte subset analysis (CD4, CD8 counts)
Assess immunocompetence before live vaccination decisions. Specialist referral required. CD4 <200 cells/Β΅L: live vaccines contraindicated.
Available
Adverse event reporting β€” TGA
Report suspected adverse events following immunisation (AEFI) via the TGA online form at www.tga.gov.au. Mandatory for serious AEFIs. Also report to state/territory health department.

Risk Stratification & Priority Groups

Identifying patients at highest risk of vaccine-preventable disease or complications is essential for prioritising vaccination in general practice.

Standard
General Population
Follow NIP schedule as per age. Annual influenza vaccination recommended for all Australians β‰₯6 months. Catch-up vaccination via AIR for any missed doses.
Setting: GP / community pharmacy
Moderate Risk
At-Risk Groups
Pregnant women, ATSI peoples, healthcare workers, travellers, people with chronic medical conditions (diabetes, CKD, chronic lung disease, cardiac disease), obesity (BMI β‰₯40).
Setting: GP with targeted recall
High Risk
Immunocompromised / Severely At-Risk
Solid organ transplant, haematopoietic stem cell transplant, asplenia/hyposplenia, HIV with CD4 <200, active chemotherapy, biologic therapy, complement deficiency. Live vaccines contraindicated; additional inactivated vaccines recommended (e.g., additional pneumococcal doses, meningococcal).
Setting: Specialist + GP co-management

Pre-Travel Vaccination

Travellers should consult a travel medicine practitioner or GP at least 4–6 weeks before departure. Non-NIP travel vaccines (e.g., yellow fever, typhoid, Japanese encephalitis, rabies, cholera) are available through private prescription and travel medicine clinics.

Monitoring & Adverse Events

Post-Vaccination Monitoring

  • Observation period: All patients should be observed for β‰₯15 minutes post-vaccination. Patients with history of anaphylaxis to any component: β‰₯30 minutes.
  • Adrenaline availability: All vaccination sites must have adrenaline (epinephrine) 1:1000 available for anaphylaxis management, along with oxygen and basic airway equipment.
  • Common expected reactions: Injection-site pain/redness (30–80%), low-grade fever (5–15%), malaise (10–30%) β€” typically resolve in 24–72 hours. Paracetamol or ibuprofen can be used for symptomatic relief.

Serious Adverse Events Following Immunisation (AEFI)

AEFI Vaccine(s) Associated Estimated Frequency Management
Anaphylaxis All vaccines ~1.3 per million doses IM adrenaline (0.01 mg/kg, max 0.5 mg), call 000, observe β‰₯4 hours.
Febrile seizure DTPa, MMR/MMRV, influenza ~1 per 3,000 (MMRV dose 1); ~1 per 10,000 (DTPa) Reassurance; does not contraindicate further doses. Differential diagnosis includes meningitis if clinically indicated.
Myocarditis/pericarditis mRNA COVID-19 (Comirnaty, Spikevax) 1–4 per 100,000 (higher in males 12–30 years) ECG, troponin, echocardiogram. Cardiology referral. Most cases mild and self-limiting.
Thrombosis with thrombocytopenia (TTS) Vaxzevria (AstraZeneca COVID-19) ~1 per 50,000 (dose 1); ~1 per million (dose 2) No longer in use in Australia. Platelets, D-dimer, PF4 antibody assay. Treat with non-heparin anticoagulation (IVIG).
Intussusception Rotavirus (Rotarix) ~1 per 50,000–100,000 doses (dose 1 risk window: 1–7 days) Symptoms: sudden inconsolable crying, vomiting, bloody stool, lethargy. Urgent surgical review.
Vaccine-associated paralytic polio (VAPP) Oral polio (not used in Australia since 2005) ~1 per 2.4 million doses Australia uses IPV exclusively β€” zero VAPP risk.
🚨
Anaphylaxis management: Administer adrenaline 1:1000 IM (anterolateral thigh) at 0.01 mg/kg (max 0.5 mg in adults, 0.3 mg in children 6–12 years, 0.15 mg in children <6 years). Repeat every 5 minutes as needed. Call 000 immediately. Place patient supine with legs elevated (if tolerated). Intramuscular route is preferred β€” do NOT use subcutaneous or intravenous route in anaphylaxis.

Australian Immunisation Register (AIR)

The AIR (managed by Services Australia) is a national register that records all vaccines given to individuals of all ages. Clinicians must report all vaccinations to the AIR. Patients can view their immunisation history via myGov.

Special Populations

🀰 Pregnancy
Recommended: Influenza (any trimester, NIP-funded), dTpa (20–32 weeks each pregnancy, NIP-funded), COVID-19 (any mRNA vaccine, any trimester).
Contraindicated: All live vaccines (MMR, varicella, MMRV, yellow fever, Zostavax). Advise contraception for 28 days after live vaccine.
Postpartum: MMR and varicella (if non-immune) can be given immediately postpartum. Safe during breastfeeding.
πŸ‘Ά Paediatrics
Birth: Hepatitis B (within 24 hours, NIP). BCG for ATSI neonates in high-incidence areas.
2–6 months: Infanrix Hexa (DTPa-hepB-IPV-Hib), Prevenar 13, Rotarix at 2 and 4 months. Minimum interval between same-antigen doses: 4 weeks.
Premature infants: Vaccinate according to chronological age (not corrected age). Same doses as term infants. Monitor for apnoea 48–72 hours post-vaccination in very preterm (<28 weeks).
School-based: HPV (Gardasil 9, single dose) and dTpa (Boostrix) at 12–13 years. MenACWY (Nimenrix) at 12–13 years.
πŸ‘΄ Elderly (β‰₯65 years)
Influenza: Fluad Quad (MF59-adjuvanted) preferred over standard quadrivalent for β‰₯65 years (NIP-funded).
Pneumococcal: 23vPPV (Pneumovax 23) β€” single dose NIP-funded at β‰₯65 years.
Herpes zoster: Shingrix (2 doses, 2–6 months apart) NIP-funded at β‰₯65 years. Safe regardless of prior Zostavax or shingles history.
COVID-19: Annual booster recommended for β‰₯75 years (ATAGI).
🩺 Renal Impairment (CKD)
Hepatitis B: Higher dose (40 Β΅g HB-Vax II) or double-dose Engerix-B. 0, 1, 2, 6 month accelerated schedule. Post-vaccination serology essential (anti-HBs β‰₯10 IU/L). Annual boosters if on dialysis and titre waning.
Pneumococcal: 13vPCV followed by 23vPPV (β‰₯8 weeks later) for CKD stage 4–5 or nephrotic syndrome.
Influenza: Annual; adjuvanted formulation preferred where available.
πŸ›‘οΈ Immunocompromised
Live vaccines: Contraindicated in severe immunodeficiency (primary immunodeficiency, HIV CD4 <200, active chemo, high-dose steroids, post-transplant). Includes MMR, varicella, MMRV, yellow fever, oral vaccines, BCG, Zostavax.
Safe and recommended: All inactivated vaccines (influenza, pneumococcal conjugate, hepatitis B, COVID-19 mRNA, Shingrix). May have reduced immunogenicity β€” consider additional doses.
Household contacts: All household members should be fully vaccinated (including live vaccines such as MMR and varicella). Rotavirus vaccine in infant contacts: discuss with immunologist.
🫁 Hepatic Disease
Hepatitis A: Recommended for all patients with chronic liver disease (Havrix 1440, 2 doses 6–12 months apart).
Hepatitis B: Recommended if non-immune. Standard dose; post-vaccination serology.
Pneumococcal: 13vPCV + 23vPPV for chronic liver disease, cirrhosis, liver transplant candidates.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health
Disease burden
Aboriginal and Torres Strait Islander peoples experience significantly higher rates of invasive pneumococcal disease (5–10Γ— higher in children), hepatitis A, hepatitis B, influenza, and rotavirus gastroenteritis compared to non-Indigenous Australians. Invasive pneumococcal disease incidence in ATSI children <2 years remains 4–6 times higher than non-Indigenous children despite universal PCV vaccination.
NIP schedule differences
ATSI infants receive additional hepatitis A vaccination (12 and 18 months in NT, Qld, SA, WA). ATSI adults β‰₯50 years receive pneumococcal 23vPPV (NIP-funded; non-Indigenous threshold β‰₯65 years). ATSI adults β‰₯50 years are eligible for Shingrix (NIP-funded; non-Indigenous threshold β‰₯65 years). MenB (Bexsero) is funded for ATSI infants in some jurisdictions.
Coverage gaps
While 5-year-old ATSI vaccination completion has improved (92.9% nationally in 2023), coverage remains below the non-Indigenous rate (94.7%). Gaps are most pronounced in remote and very remote areas, and among ATSI adolescents.
Access barriers
Geographic isolation in remote communities limits access to GP and pharmacy vaccination services. Aboriginal Community Controlled Health Organisations (ACCHOs) are critical providers of immunisation services. Cold-chain logistics in remote areas (e.g., maintaining 2–8Β°C during transport) require specialised planning and equipment.
Cultural considerations
Culturally safe vaccination delivery through ACCHOs, Aboriginal Health Workers, and community engagement improves uptake. Acknowledging the role of Elders and community leaders in health messaging. Addressing vaccine hesitancy through trusted community voices, not solely top-down government messaging.
Key recommendations
Ensure ATSI patients receive all NIP-funded vaccines with appropriate age thresholds (earlier pneumococcal, zoster, hepatitis A). Promote influenza vaccination for all ATSI people β‰₯6 months (NIP-funded). Support ACCHOs in maintaining cold-chain integrity in remote communities. Report vaccination data to AIR to enable accurate coverage monitoring.

πŸ“š References

  1. 1. Australian Government Department of Health and Aged Care. Australian Immunisation Handbook. Canberra: Australian Government; 2024. Available from: https://immunisationhandbook.health.gov.au
  2. 2. Australian Technical Advisory Group on Immunisation (ATAGI). ATAGI recommendations on the use of COVID-19 vaccines. Canberra: Australian Government Department of Health and Aged Care; 2024.
  3. 3. National Centre for Immunisation Research and Surveillance (NCIRS). Annual Immunisation Coverage Report, 2023. Sydney: NCIRS, University of Sydney; 2024.
  4. 4. World Health Organization (WHO). Global Vaccine Action Plan 2011–2020: Review and lessons learned. Geneva: WHO; 2020.
  5. 5. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new understandings. Nature Reviews Immunology. 2021;21(2):83–100.
  6. 6. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework 2023: summary report. Canberra: AIHW; 2023.
  7. 7. Pittet LF, Curtis N. Adjuvants in vaccines: the search continues. The Lancet Infectious Diseases. 2023;23(5):e182–e185.
  8. 8. Weinberger B. Adjuvants for vaccines in the elderly β€” mechanisms and future perspectives. Vaccines. 2023;11(3):634.
  9. 9. Therapeutic Goods Administration (TGA). Database of Adverse Event Notifications (DAEN). Canberra: Australian Government; 2024. Available from: https://www.tga.gov.au
  10. 10. Nolan T, et al. Safety and immunogenicity of the AS01B-adjuvanted herpes zoster subunit vaccine in adults β‰₯50 years: a phase III randomised controlled trial. The Lancet. 2016;388(10056):2105–2116.
  11. 11. Dey A, Gidding HF, Menzies RI, et al. Australia's National Immunisation Program: coverage trends and implications. Medical Journal of Australia. 2024;220(4):198–204.
  12. 12. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. New England Journal of Medicine. 2020;383(27):2603–2615.
  13. 13. Australian Government Services Australia. Australian Immunisation Register (AIR). Canberra: Services Australia; 2024.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

πŸ“š References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, LandewΓ© RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing β€” misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFΞ± blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

πŸ“š References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, LandewΓ© RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing β€” misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFΞ± blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).